These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 37026950

  • 1. Ischaemic colitis during pegylated interferon-alpha monotherapy for chronic hepatitis B: A case report.
    Liu Y, Chen H, Xu ZY.
    Medicine (Baltimore); 2023 Apr 07; 102(14):e33378. PubMed ID: 37026950
    [Abstract] [Full Text] [Related]

  • 2. Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report.
    Baik SJ, Kim TH, Yoo K, Moon IH, Cho MS.
    World J Gastroenterol; 2012 Aug 21; 18(31):4233-6. PubMed ID: 22919260
    [Abstract] [Full Text] [Related]

  • 3. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
    Leung Y, Urbanski SJ, Schindel L, Myers RP.
    Can J Gastroenterol; 2006 Oct 21; 20(10):661-3. PubMed ID: 17066158
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
    Hu Y, Ye YZ, Ye LJ, Wang XH, Yu H.
    World J Pediatr; 2019 Dec 21; 15(6):595-600. PubMed ID: 31487005
    [Abstract] [Full Text] [Related]

  • 5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J, Jones J, Takeda A, Davidson P, Price A.
    Health Technol Assess; 2006 Aug 21; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P, Lenci I, di Paolo D, Demelia L, Sorbello O, Nosotti L, Angelico M.
    Antivir Ther; 2013 Aug 21; 18(1):57-64. PubMed ID: 22872648
    [Abstract] [Full Text] [Related]

  • 8. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L, Mari T, De Santis A, Ponti ML, Sorbello O, Iacomi F, Angelico M.
    Antivir Ther; 2009 Aug 21; 14(8):1165-74. PubMed ID: 20032546
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study.
    Liu YH, Wu T, Sun N, Wang GL, Yuan JZ, Dai YR, Zhou XH.
    J Huazhong Univ Sci Technolog Med Sci; 2014 Aug 21; 34(4):542-547. PubMed ID: 25135724
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, van Nieuwkerk CMJ, Zaaijer HL, Molenkamp R, Takkenberg RB, Koot M, Verheij J, Beuers U, Reesink HW.
    Lancet Gastroenterol Hepatol; 2017 Aug 21; 2(8):576-584. PubMed ID: 28522204
    [Abstract] [Full Text] [Related]

  • 13. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X, Yu JX, Xie L, Ma WJ, Wang LH.
    Ann Hepatol; 2017 Aug 21; 16(6):888-892. PubMed ID: 29055925
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
    Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, Lee A, Rusli F, Chen R, Bell S, Pianko S, Sievert W.
    J Gastroenterol Hepatol; 2012 Sep 21; 27(9):1447-53. PubMed ID: 22168789
    [Abstract] [Full Text] [Related]

  • 15. Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C.
    Choi JW, Lee JS, Paik WH, Song TJ, Kim JW, Bae WK, Kim KA, Kim JG.
    Clin Mol Hepatol; 2016 Mar 21; 22(1):168-71. PubMed ID: 27044768
    [Abstract] [Full Text] [Related]

  • 16. Pegylated-interferon alpha (PEG-IFNα)-induced interstitial lung disease in a patient with chronic hepatitis B: A case report and literature review.
    Shi M, Wang S, Ren Y, Zhao L, Liu M, Yang L, Yang T.
    Int J Clin Pharmacol Ther; 2024 Aug 21; 62(8):386-394. PubMed ID: 38699975
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB, Golge N, Akin MS.
    Eur J Gastroenterol Hepatol; 2013 Nov 21; 25(11):1312-6. PubMed ID: 23652913
    [Abstract] [Full Text] [Related]

  • 19. [Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin].
    Iferkhass S, Elasri F, Chatioui S, Khoyaali A, Bargach T, Reda K, Oubaaz A.
    J Fr Ophtalmol; 2015 Jan 21; 38(1):34-40. PubMed ID: 25533994
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.